Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients.

Clinical chemistry and laboratory medicine - 19 Dec 2018

Song Tao, Mao Fei, Shi Li, Xu Xuemei, Wu Zirong, Zhou Juan, Xiao Meifang

Abstract excerpt

Background Solid tumor tissue testing is the gold standard for molecular-based assays for metastatic colorectal cancer (mCRC). This poses challenges during treatment monitoring. Total DNA derived from urine specimens offers clear advantages to track the disease dynamics. Our study aims to evaluate the sensitivity for total DNA recovered from urine and its clinical relevance to mCRC. Methods KRAS mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Monitoring, Physiologic

Share to Mutation

Share to Neoplasm Metastasis

Share to Prognosis

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 30016269
DOI: 10.1515/cclm-2017-0675

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients.PMID 30016269Read ↗

Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.Semantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.Semantic proximity Read ↗

Circulating tumor DNA in colorectal cancer: biology, methods and applicationsSemantic proximity Read ↗

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity Read ↗

Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and predictionSemantic proximity Read ↗

Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.Semantic proximity Read ↗

Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer.Semantic proximity Read ↗

Screening, Prognostic, and Predictive Molecular Tools for Colorectal Cancer: Recent Advances in the Classical Background.Semantic proximity Read ↗

Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.Semantic proximity Read ↗

Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.Semantic proximity Read ↗

Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.